Medivir — Share Issue/Capital Change 2010

Oct 29, 2010

Press Release 29 October 2010

Increased number of shares and votes in Medivir

Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, today announces that the number of shares and the number of votes in Medivir have changed as a result of exercise of employee stock options.

Today, the last trading day of the month, there are in total 26,250,591 shares and 32,190,591 votes in Medivir.

For additional information, please contact;

Rein Piir, CFO & VP Investor Relations, Medivir; +46 8 54683123 or +46 708 537 292.

About Medivir

Medivir is a research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese™/Xerclear® . Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese™/Xerclear® is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website: www.medivir.se